NXP900
Advanced solid tumors
Key Facts
About Nuvectis Pharma
Nuvectis Pharma is a clinical-stage oncology company focused on developing innovative, targeted small molecules for serious cancers with limited treatment options. Its lead asset, NXP900, is a first-in-class Type 1.5 SRC/YES1 inhibitor designed to completely shut down oncogenic signaling, while NXP800 represents a novel approach via GCN2 activation. The company's strategy centers on precision medicine, advancing programs through clinical proof-of-concept with a lean, experienced team that has a proven track record of guiding drugs to market. Nuvectis is publicly traded on NASDAQ under the ticker NVCT.
View full company profileAbout Nuvectis Pharma
Nuvectis Pharma is a clinical-stage oncology company focused on developing innovative, targeted small molecules for serious cancers with limited treatment options. Its lead asset, NXP900, is a first-in-class Type 1.5 SRC/YES1 inhibitor designed to completely shut down oncogenic signaling, while NXP800 represents a novel approach via GCN2 activation. The company's strategy centers on precision medicine, advancing programs through clinical proof-of-concept with a lean, experienced team that has a proven track record of guiding drugs to market. Nuvectis is publicly traded on NASDAQ under the ticker NVCT.
View full company profileTherapeutic Areas
Other Advanced solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |